|Bid||7.80 x 800|
|Ask||8.33 x 2900|
|Day's Range||8.04 - 8.23|
|52 Week Range||7.57 - 13.99|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.33|
Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high. To...
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its first quarter 2021 financial results and provided a business update.
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.